Browse MMP10

Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF00045 Hemopexin
PF00413 Matrixin
PF01471 Putative peptidoglycan binding domain
Function

Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. Activates procollagenase.

> Gene Ontology
 
Biological Process GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030574 collagen catabolic process
GO:0032963 collagen metabolic process
GO:0043062 extracellular structure organization
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0008237 metallopeptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-1442490: Collagen degradation
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-162582: Signal Transduction
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MMP10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MMP10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MMP10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1050.853
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6690.463
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3150.691
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.0710.0683
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.3260.154
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.7480.358
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4830.571
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.9770.469
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2150.891
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3710.468
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3710.614
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.5638.74e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MMP10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MMP10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MMP10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMMP10
Namematrix metallopeptidase 10
Aliases STMY2; matrix metalloproteinase 10 (stromelysin 2); stromelysin 2; SL-2; MMP-10; matrix metalloprotease 10; ......
Chromosomal Location11q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MMP10 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MMP10.
ID Name Drug Type Targets #Targets
DB00786MarimastatSmall MoleculeMMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......23
DB08271N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACIDSmall MoleculeMMP10, MMP12, MMP20, MMP34